Skip to main content

Table 2 Relationship between NLRs and clinical factors

From: An increase in the neutrophil-to-lymphocyte ratio during adjuvant chemotherapy indicates a poor prognosis in patients with stage II or III gastric cancer

Factor pNLR (+) pNLR (−) P-value iNLR (+) iNLR (−) P-value fNLR (+) fNLR (−) P-value
Sex (M/F) 34/16 39/11 0.368 23/ 3 50/24 0.043 28/10 45/17 1.000
Age (< 65/≥65 years) 21/29 20/30 1.000 11/15 30/44 0.875 16/22 25/37 1.000
Tumor size (< 60/≥60 mm) 20/30 28/22 0.161 14/12 34/40 0.504 16/22 32/30 0.412
Histologic type (Diff/Undiff) 15/35 20/30 0.402 8/18 27/47 0.644 11/27 24/38 0.390
pT (1/2/3/4) 1/ 6/18/25 4/ 6/23/17 0.275 2/ 4/10/10 3/ 8/31/32 0.731 2/ 7/11/18 3/ 5/30/24 0.180
pN (0/1/2/3) 4/11/14/21 10/14/17/ 9 0.045 2/11/ 9/ 4 12/14/22/26 0.056 3/ 9/14/12 11/16/17/18 0.510
pStage (II/III) 13/37 26/24 0.013 12/14 27/47 0.484 15/23 24/38 1.000
Lymphatic invasion (+/−) 43/ 7 37/13 0.211 21/ 5 59/15 1.000 28/10 52/10 0.303
Venous invasion (+/−) 40/10 38/12 0.810 20/ 6 58/16 1.000 30/ 8 48/14 1.000
Recurrence (+/−) 22/28 13/37 0.093 9/17 26/48 1.000 24/14 11/51 < 0.001*
Outcome (D/A) 17/33 7/43 0.034 8/18 16/58 0.425 18/20 6/56 < 0.001*
  1. M, male; F, female; Diff, differentiated type; Undiff, undifferentiated type; pT, pN, pStage = pathological T stage, N stage. Pathological cancer stage according to the 8th edition of the American Joint Committee on Cancer (AJCC) Cancer Staging Manual; pNLR, preoperative neutrophil-to-lymphocyte ratio; iNLR, the ratio of the NLR on the initial day of adjuvant chemotherapy to the pNLR; fNLR, the ratio of the NLR on the final day of adjuvant chemotherapy to the iNLR; D/A, dead or alive; *P-value indicates statistical significance after false discovery rate correction
\